血液系统恶性肿瘤研究进展

Progress of hematological malignant tumors

美国血液学会（ASH）年会是全球最具影响力的血液学会议，会议报道的研究成果体现了当今血液病从基础研究到临床实践，从诊断到治疗的最新进展。第59届ASH年会内容涵盖了从急性髓系白血病标准治疗的改进到侵袭性B细胞淋巴瘤的治疗策略，从骨髓增生异常综合征的治疗前景到生物学特性对惰性淋巴瘤治疗决策的影响，从慢性淋巴细胞白血病的个体化治疗到获得性／遗传性骨髓衰竭的研究等课题。中国学者近年来也取得了出色的研究成果，获得了国际同行的好评。

The 59th American Society of Hematology （ASH） Annual Meeting is known as the most powerful hematological meeting around the world. The outcomes in the meeting showed the progress of current hematological diseases from the fundamental research to the clinical practice, from the diagnosis to the treatment. The 59th ASH Annual Meeting covered the contents from the improvement of the formal treatment of acute myelogenous leukemia to the strategies of the aggressive B-cell lymphoma, from the prospect on myelodysplastic syndromes to the influence of biological features on the treatment strategies of indolent lymphoma, from the individualized treatment of chronic lymphocytic leukemia to the study on acquired or hereditary bone marrow failure. The inspiring outcomes from the scholars in China have gained good reputations from the international.